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Abstract The analysis of mutations that are associated with
the occurrence of drug resistance is important for monitoring
the antiretroviral therapy of patients infected with human
immunodeficiency virus (HIV). Here, we describe the
establishment and successful application of Arrayed Primer
Extension(APEX) forgenotypic resistancetestinginHIVasa
rapid and economical alternative to standard sequencing. The
assay is based on an array of oligonucleotide primers that are
immobilised via their 5′-ends. Upon hybridisation of template
DNA,aprimerextensionreactionisperformedinthepresence
of the four dideoxynucleotides, each labelled with a distinct
fluorophore. The inserted label immediately indicates the
sequence atthe respectiveposition. Any mutation changes the
colour pattern. We designed a microarray for the analysis of
26 and 33 codons in the HIV protease and reverse
transcriptase, respectively, which are of special interest with
respect to drug resistance. The enormous genome variability
of HIV represents a big challenge for genotypic resistance
tests, which include a hybridisation step, both in terms of
specificity and probe numbers. The use of degenerated
oligonucleotides resulted in a significant reduction in the
number of primers needed. For validation, DNA of 94 and 48
patients that exhibited resistance to inhibitors of HIV protease
and reverse transcriptase, respectively, were analysed. The
validation includedHIV subtype B, prevalent inindustrialised
countries, as well as non-subtype B samples that are more
common elsewhere.
Keywords ArrayedPrimer Extension(APEX).
Oligonucleotidemicroarray.Humanimmunodeficiency
virus(HIV).Genotypicdrugresistancetesting
Introduction
AIDS—acquired immunodeficiency syndrome—was first
reported in 1981 and has since become a worldwide
pandemic. Currently some 40 million people are HIV-
infected (http://www.who.int/). Antiviral treatment is based
on the use of drugs which inhibit HIV reverse transcriptase
(RT) and protease (PR). The emergence of resistant viruses
is a major obstacle to the long-term effective and successful
therapy of HIV-infected patients. Antiviral drug resistance
is caused by the presence of mutations in the PR and RT
coding regions of the virus that reduce drug susceptibility
compared to wild-type viruses (see e.g. [1]). Drug resis-
tance can be determined by genotypic tests that identify
resistance-related mutations in the viral genome [2].
Therefore, genotypic resistance testing has become an
increasingly important process when monitoring the anti-
retroviral therapy of patients infected with HIV [3–7].
HIV genotypic resistance data are mostly obtained during
the clinical routine by dideoxy sequencing [8] which is a time-
consuming process. Alternative methods for genotypic
resistance testing are needed. Therefore, several different
approaches have been described in the last few years, based
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methods [11]. Because of the tremendous variability of the
viral genome, the two last approaches were restricted to a few
selected mutations, however. In consequence, primary muta-
tions were assayed but secondary mutations were not
included. Primary mutations are directly responsible for
resistance. Secondary or accessory mutations often cause
resistance when present in combination with other mutations
or compensate for the diminished replicate activity that can be
associated with drug resistance [2]. The assay reported by
Gonzalez et al. [9] covered a wide range of mutations based
on the microarray technology developed by Affymetrix. Even
with the large number of oligonucleotides that can be placed
on this chip, however, it is difficult to achieve clinically
reliable results, since the analysis is based merely on
hybridisation discrimination and is therefore prone to being
obscured by the high degree of sequence variance in HIV.
Here, we show the development and validation of a cost-
effective and rapid HIVresistance test that allows the detection
of the mutations in PR and RT that are reported as being
resistance-related by the Stanford HIV database http://hivdb.
stanford.edu/). It is based on the Arrayed Primer Extension
method (APEX; [12]), a process used to detect single
nucleotide polymorphisms in a target DNA. By virtue of the
combination of the discriminative effect of the hybridisation
process and the base-pairing specificity of the DNA-
polymerase used for the extension reaction, the overall
accuracy of the reaction can be increased 10- to 100-fold
compared to merely hybridisation-based assays [13, 14].
Template-dependent extension of the arrayed primers in the
presence of the four different dideoxynucleotides, each labelled
with a particular fluorophore, yields sequence information.
Mutations can be detected by a change in the signal colour at
the respective array position. In order to minimise the number
of oligonucleotides while at the same time being able to analyse
all relevant mutations in PR and RT, the applicability of
degenerated oligonucleotides was also studied. A primer is
called degenerated if several bases are possible at some of its
sequence positions. Degenerated oligonucleotides have been
found to be useful in PCR [15] and hybridisation assays (e.g.
[16]), for example. The final objective was an adaptation of
the APEX technology to the challenges provided by the high
mutability of the HIV genome and the development of a
quick, efficient and inexpensive genotypic test system for
high-throughput clinical applications.
Materials and methods
Sample collection
To evaluate the APEX-based genotypic resistance assay, 94
and 48 HIV-1 positive clinical samples from patients that
exhibited resistance to inhibitors of HIV protease and reverse
transcriptase, respectively, were analysed. The patient-
derived PCR-products were chosen randomly from routine
clinical testing at the Department of Virology, University of
Heidelberg. For all PCR products, the sequences were
determined by Sanger sequencing using the ViroSeq geno-
typing kit (Abbott, Wiesbaden, Germany). Phylogenetic
analysis showed that 76% (71/94) of the PR samples and
87% (41/48) samples of the RT region belonged to HIV-1
subtype B. The non-subtype B samples consisted of A, C,
F1, CRF01_AE, CRF01_AG, CRF02_AG and CRF06_cpx
(Rega HIV-1 Subtyping Tool,[ 17]).
Template preparation
For re-amplification, 5-μl aliquots of the original PCR-products
were used as template. The 50 μl reaction mix consisted of 0.25
mM dNTPs, 0.3 mM each of forward and reverse primer, 1.25
U Thermoprime Plus DNA polymerase and reaction buffer
(ABgene, Hamburg, Germany). 15% of the dTTP was replaced
with dUTP in order to introduce dUTP randomly. For
amplification, primers d(GGGAAGATCTGGCCTTCCTA
CAA) and d(GGGCCATCCATTCGTGGC) were used for
PR and d(CACCTGTCAACATAATTGGA) and d(ACTGTC
CATTTATCAGGATG) for the RT region. The PCR primers
were synthesised by biomers (Ulm, Germany).
PCR began with an initial denaturation step at 94 °C for 2
min followed by 30 cycles at 94 °C for 30 s, 56 °C for 30 s
and 72 °C for 2.5 min, and a final extension at 72 °C for 10
min. PTC-200 ThermoCyclers (MJ Research, Waltham MA,
USA) were used for all amplifications. The expected
fragment lengths of 559 bp (PR) and 780 bp (RT) were
checked on 2% agarose gels. One hundred microlitres of
PCR mix were concentrated and purified with a QIAquick
PCR Purification Kit (Qiagen, Hilden, Germany), as recom-
mended by the manufacturer, and eluted in 30 μlH 2O.
Finally, 20 μl of each PCR product was fragmented by
incubation with 0.1 U uracil-N-glycosylase in a reaction
buffer of 50 mM Tris/HCl pH 9, 20 mM (NH4)2SO4)a t
37 °C for 1 h. The enzyme was deactivated at 95 °C for 10
min, and an aliquot of digested DNA was again checked on
an agrose gel.
Production of the oligonucleotide microarrays
All oligonucleotides were purchased from biomers (Ulm,
Germany) or MWG (Ebersberg, Germany). Each one was 50
nucleotides in length, containing a C6-aminolinker and a 20-
25mer oligo-dT spacer at the 5′-end. Attachment to epoxysi-
lane-coated glass slides (Schott Nexterion Slide E, Mainz,
Germany) occurred via the 5′-C6-aminolinker to ensure the
accessibility of the 3′-terminus for the enzymatic reaction. The
final spotting solution contained 50 μM oligonucleotide in
1662 Anal Bioanal Chem (2008) 391:1661–16690.05 Msodium carbonate,0.1M sodium citrate,pH9.5,with 3
M betaine.
InadditiontotheHIV-specificprimers,twokindsofcontrols
were included in the chip layout. First, 25-mer oligonucleotides
that carried at their 3′-end the fluorescence labels Cy3, Cy5,
TexasRed or Fluorescein, respectively, were utilised as posi-
tional controls (5′-TGGGTATAAACGATTTCGTAGATAA-
dye). A mixture of the four differently labelled oligonucleotides
(12.5 μM each) was spotted onto the microarray. Second, to
control the primer extension reaction an oligonucleotide was
applied that forms a hairpin structure (NACGACCGACTT
TAGGTCCCTCAATTTTTGAGGGACCTA
AAGTCGGTCGT),thus actingas bothprimerand template. In
analogy to the molecules that represent HIV sequences, all
controls had a C6 aminolinker and an oligo-dT spacer at their
5′-ends.
For microarray production, the SDDC-2 Chip Writer
contact printing robot (Engineering Services, Toronto, ON,
Canada) was used. Equipped with SMP 3-pins (TeleChem,
Sunnyvale, CA, USA), each contact delivered a volume of
approximately 1 nl. All oligonucleotides were spotted in
duplicate. After spotting, slides were incubated at 60 °C for
1 h and stored at room temperature for at least 24 h.
Arrayed primer extension
Directly before an APEX reaction was performed, the micro-
arrays were washed twice in H2O at 95 °C to remove residual
spotting solution. To block the surface, slides were incubated
in 100 mM NaOH for 10 min at room temperature and
washed again in H2O at 95 °C. The primer extension was
carried out directly on the slide surface in a reaction chamber
formed by a 20 μl frame-seal (ABgene, Hamburg, Germany).
As estimated from a comparison to a 100 bp DNA marker
ladder (MBI Fermentas, St. Leon-Roth, Germany), 600–800
ng of PCR product were used in each APEX reaction. The
20-μl reaction mix contained 10 μl of fragmented PCR prod-
uct, 4 U ThermoSequenase DNA polymerase (Amersham,
Freiburg, Germany), ThermoSequenase reaction buffer
(Amersham) and 1.25 μMe a c ho fd d A T P - T e x a s R e d ,
ddCTP-Cy3, ddGTP-Fluorescein and ddUTP-Cy5 (Perkin
Elmer, Boston, MA, USA). The mix of buffer, labelled
ddNTPs and target DNA were first denatured for 10 min at
95 °C before adding the DNA polymerase. The mix was
subsequently loaded onto the microarray, and the reaction
chamber was covered with a plastic film.
The slides were placed into a ThermoCycler PTC-200,
TwinTower (MJ Research, Waltham, MA, USA). Tempera-
ture profiles were used as shown in Table 1. After the primer
extension reaction, the slides were immediately washed in
water at 95 °C, for 3 min in 0.3% Alconox (Alconox, White
Plains, NY, USA), again in water at 95 °C, and finally in 30
mM NaCl, 3 mM Na3 citrate (pH 8.5) in order to obtain
optimal pH conditions for all four fluorescent dyes. Slides
were dried in an air flow.
Signal analysis
Signal detection was performed by confocal four-colour laser
scanners (ScanArray 4000XL and ScanArray 5000, Perkin
Elmer, Boston, MA, USA). Intensities were measured using
GenePix 4.0 quantification software (Axon Instruments, Union
City, CA, USA). The data were normalised based on the
quantum yields of the four fluorescent dyes and different
hybridisationpropertiesoftheoligonucleotidesusingasoftware
tool developed in-house. The output files presented a base call
for each nucleotide position and allowed a direct comparison
with the reference sequences obtained by Sanger sequencing.
Results and discussion
Optimisation of APEX conditions
The application of APEX for HIV resistance testing
required some modifications to the reaction conditions as
described by Kurg et al. [12] for standard genotyping. Each
oligoucleotide had a 20–25mer portion of oligo-d(T) at its
5′-end to reduce steric hindrance effects. Spotting the
oligonucleotides in sodium carbonate buffer (pH 9) pro-
duced the best signal-to-background ratios. The addition of
3 M betaine to the spotting solution improved spot
homogeneity [18]. Furthermore, in contrast to the temper-
ature profile described by Kurg et al. [12], primer extension
was not carried out as a one-step reaction at 48 °C. At least
three steps were needed for denaturation, hybridisation and
specific primer extension in order to obtain significant
Table 1 Temperature profile of the APEX reactions for the PR and
RT oligonucleotides
Denaturation 95 °C 30 sec
PR chip Hybridisation 40 °C 10 min
Extension 68 °C 15 min
RT chip Hybridisation 40 °C 10 min
Extension 68 °C 15 min
Hybridisation 40 °C 10 min
Extension 66 °C 15 min
Hybridisation 40 °C 10 min
Extension 64 °C 15 min
Hybridisation 40 °C 10 min
Extension 62 °C 15 min
Hybridisation 40 °C 10 min
Extension 60 °C 15 min
Hybridisation 40 °C 10 min
Extension 58 °C 15 min
Ramping of the in situ cycler occurred at 1 °C / s
Anal Bioanal Chem (2008) 391:1661–1669 1663signal intensities at the PR oligonucleotides (Table 1).
Dissociation temperatures were even more variable for the
RT oligonucleotide primers. Therefore a multi-step gradient
profile was established (Table 1).
Degenerated oligonucleotide primers
Becauseofitsreplicationcycle,HIVshowsimmensesequence
heterogeneity [19–22]. To effectively analyse a wide range of
samples, it is necessary to represent this very high sequence
variety on the microarray. In order to reduce the number of
oligonucleotides needed, the effects of wobble positions (a
mixture of bases at the particular nucleotide) and substitution
with inosine was investigated. The most polymorphic region
of the PR gene was used as a model. It is located around
codon 71. In total, 13 positions of the 20-mer primer that was
used to query the nucleotide at sequence position 211 are not
conserved. A probe representing the wildtype sequence was
used as a control. In derivative molecules, more and more
variable positions were replaced by degenerate bases, starting
either from the 5′-end or 3′-end (Table 2). In one oligonu-
cleotide (W13), all variable positions were degenerated.
Oligonucleotide extension was performed at the conditions
described in the “Materials and methods” section. Using a
wild-type DNA-template, Cy3-ddCTP was incorporated. As
shown in Fig. 1, increasing the number of degenerated
Table 2 Degenerated primers for APEX reaction: sequences of a model system
Probe Name Sequence No. of degenerated 
positions
unmodified TACTAATACTGTACCTATAG 0
5W1 YACTAATACTGTACCTATAG 1
5W2 YAYTAATACTGTACCTATAG 2
5W3 YAYYAATACTGTACCTATAG 3
5W4 YAYYARTACTGTACCTATAG 4
5W5 YAYYARYACTGTACCTATAG 5
5W6 YAYYARYACTGWACCTATAG 6
5W7 YAYYARYACTGWRCCTATAG 7
5W8 YAYYARYACTGWRCYTATAG 8
5W9 YAYYARYACTGWRCYYATAG 9
5W10 YAYYARYACTGWRCYYDTAG 10
5W11 YAYYARYACTGWRCYYDYAG 11
5W12 YAYYARYACTGWRCYYDYDG 12
W13 YAYYARYACTGWRCYYDYDR 13
unmodified TACTAATACTGTACCTATAG 0
3W1 TACTAATACTGTACCTATAR 1
3W2 TACTAATACTGTACCTATDR 2
3W3 TACTAATACTGTACCTAYDR 3
3W4 TACTAATACTGTACCTDYDR 4
3W5 TACTAATACTGTACCYDYDR 5
3W6 TACTAATACTGTACYYDYDR 6
3W7 TACTAATACTGTRCYYDYDR 7
3W8 TACTAATACTGWRCYYDYDR 8
3W9 TACTAAYACTGWRCYYDYDR 9
3W10 TACTARYACTGWRCYYDYDR 10
3W11 TACYARYACTGWRCYYDYDR 11
3W12 TAYYARYACTGWRCYYDYDR 12
W13 YAYYARYACTGWRCYYDYDR 13
Degenerated positions are marked in red. Abbreviations are used according to the IUB code
1664 Anal Bioanal Chem (2008) 391:1661–1669positions within the primer sequence led to a decrease in the
signal. Oligonucleotides with 1–5 wobble positions at the 5′-
terminus exhibited reduced but still significant signal
intensities compared to the unmodified probe (Fig. 1a). In
contrast, the introduction of even one wobbling base at the
3′-end (3W1) reduced signal intensity dramatically. No
significant signal could be detected with oligonucleotides
that had more than one degenerated position near the 3′-end
(Fig. 1b). Additional experiments with inosine and other
sequences produced similar results (data not shown). Even
though inosine should base-pair with all four bases, although
to a reduced degree, its introduction close to the 3′-end
resulted in a complete loss of signal.
Based on these results, the oligonucleotides for the
microarray were designed in such a way that no more than
four wobble nucleotides or inosines were introduced as
close to the 5′-terminus as possible. This strategy allowed
an ~16-fold reduction in the number of primers needed on
the chip for genotypic testing of all major resistance sites in
HIV.
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Fig. 1a,b Impact of degener-
ated primers on APEX. Wobble
sequences were introduced into
the wild-type sequence at 13
positions of variable bases of a
20-mer primer starting from the
5′-end (a) or the 3′-end (b), as
shown in Table 2. The effect on
signal intensities that resulted
from a primer extension reaction
on wild-type DNA is presented
635 nm 
Cy5-T
594 nm
TexasRed-A
488 nm
Fluorescein-G
523 nm
Cy3-C
Fig. 2 Typical results from a
primer extension reaction on the
PR oligonucleotides with the
four labelled dideoxynucleo-
tides. The array was scanned at
the wavelengths that are optimal
for the detection of the individ-
ual dyes
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The final assay was designed to detect the key mutations
which are associated with the development of drug
resistances in HIV-1. The selection of codons within the
HIV-1 PR and RT coding regions was based on the drug
resistance summaries in the Stanford HIV database http://
hivdb.stanford.edu/), which had 15,380 entries. In essence,
there are 26 relevant codons (78 nucleotide positions) in the
protease gene and 33 codons (99 nucleotide positions) in
the reverse transcriptase gene. The design of the oligonu-
cleotides was based on the Los Alamos HIV sequence
database http://hiv-web.lanl.gov/content/index). All se-
quence variations described as resistance-related and
present in more than 5% or 10% of the cases of resistance
to inhibitors of PR or RT, respectively, were covered by
oligonucleotides on the chip. In total 368 PR-and 523 RT-
specific oligonucleotides were spotted in duplicate onto the
microarray (for sequences see the “Electronic Supplemen-
tary Information”). Fluorescently labelled oligonucleotides
were used for positional control. Additionally, oligonucleo-
tides that are able to self-extend by forming hairpin
structures were introduced into the chip layout as a
template-independent control for the primer extension
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Fig. 3 Concordance of the APEX results with data from standard
sequencing. DNA from 94 and 48 patients that exhibited resistance to
inhibitors of HIV protease and reverse transcriptase were analysed in
26 resistance-related codons of the PR and 33 codons of the RT genes.
The data were compared to results obtained by standard Sanger
sequencing of the same samples
Table 3 Analysis of non-subtype B samples
Subtype No. of samples No. of analysed positions Concordance Partial concordance Discordant results
PR Subtype B 71 5538 94% (5177) 2% (88) 5% (273)
Non-subtype B 23 1794 88% (1573) 2% (51) 10% (170)
RT Subtype B 41 4059 87% (3542) 3% (129) 10% (388)
Non-subtype B 7 693 84% (580) 4% (27) 12% (86)
1666 Anal Bioanal Chem (2008) 391:1661–1669reaction; they represent template and primer at the same
time (for sequences see “Materials and methods”). Figure 2
shows typical results from an APEX reaction on the PR
oligonucleotides. The microarray was scanned at the
wavelengths correlating to the four fluorescence dyes
attached to the four dideoxynucleotides.
Initial validation of the APEX assay in comparison
to standard sequencing
In the analysis, patient samples were investigated that had
been obtained from ongoing routine testing at the Depart-
ment of Virology of the University of Heidelberg. The
analysis was approved by the local ethics committees at the
University of Heidelberg, and informed consent was
obtained from all patients. The set used for validation was
randomly chosen and independent of subtype, drug regi-
mens or the presence of special genotypes. A total of 7,332
relevant nucleotide positions were analysed by APEX for
the HIV PR region (78 nucleotides × 94 patient samples)
and 4,752 for the HIV RT gene (99 nucleotides × 48 patient
samples) and compared with the results obtained by
standard Sanger sequencing as a reference method.
For the PR gene, 92% (6,750 nucleotides) of the
sequence information was in full agreement, while 6%
(443) did not match entirely. About 2.5% (165) of the
conflicting positions were due to unassigned nucleotides.
For codons 10 and 36, for example, detection efficiency
was low. Weak signal intensities were defined as (false)
negatives, since it was impossible to determine the
sequence with the stringent filter criteria applied. Another
2% (139) of the positions partially matched in APEX and
sequencing since they yielded more than one base.
Nucleotide mixtures that are only detected in the APEX
assay but not in standard sequencing could occur because
of the higher sensitivity of the APEX method to the
presence of two bases at one site. The analysis software for
standard sequencing often suppresses the weaker signal of
primer set 1 primer set 2
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Fig. 4 Improving concordance by
replacing ill-performing primers.
For ten positions in codons 23, 30,
47, 60, 62, 63, 76 and 93 that were
not detected well with the initial
primer set, oligonucleotides were
designed to query the same sites on
the second DNA strand. Four
patientsampleswereanalysedeight
times. Comparison of the overall
performanceof the initialprimerset
(blue) with the modified primer set
(red) indicates a significant im-
provement, even though only a
few primers had been replaced
Fig. 5 Biplot representation of
the results from a correspon-
dence analysis of the PR data.
The different polymorphisms are
shown as black dots. Each red
square represents a patient sam-
ple. The majority of samples fall
into two clusters which are
highly associated with particular
groups of mutations
Anal Bioanal Chem (2008) 391:1661–1669 1667the two. Different results between APEX and Sanger
sequencing were definitely obtained, mostly for secondary
mutations, especially codons 63 and 71 in the protease.
These positions are located within the most polymorphic
region; more specific rather than degenerated primers are
needed at these sites. Concordance for the investigated RT
samples was 86% (4,099), partial concordance 4% (161)
and discordance 10% (492). A portion of 5% (234) of the
positions identified as different were false negatives.
Figure 3 shows the degree of concordance between APEX
and Sanger sequencing for the individual 26 codons in the
PR gene and 33 codons of the RT gene.
Phylogenetic analysis of RT and PR sequences
At least nine different genetic HIV-1 subtypes and several
recombinant forms exist [23]. Since subtype B is the
predominant subtype in highly industrialised countries, most
HIV-1 sequence data in databases is subtype B, even though
subtype B is responsible for only 12% of global infections
[24]. Since sequences from the Los Alamos HIV database
were used as basis for the chip design, the microarray
currently represents mainly subtype B sequences.
Validation of our APEX genotyping assay was done with
subtype B as well as non-subtype B samples. A phylogenetic
analysis according to De Oliveira et al. [17]o ft h eP Ra n dR T
samples used in our chip validation process showed that 71 of
94 (PR) and 41 of 48 (RT) sequences belonged to subtype B.
The others consisted of subtypes A, C, F1 and recombinant
A/G and A/E viruses. Table 3 shows a comparison of the
results for subtype B and non-subtype B samples. Focusing
only on subtype B samples, concordance values of 94% and
88% were obtained for PR and RT, respectively. In
comparison, the values for non-subtype B samples were
88% and 84%. Although the concordance of the APEX
results with the reference method was a little lower for non-
subtype B samples, the oligonucleotide set selected purely on
subtype B sequences produced a base calling of sufficient
accuracy to be used for non-subtype B samples.
Improvement in APEX detection
In general, the quality of the results from an APEX reaction
depends on the functioning of the relevant primers. It is
well documented that particular sequences may not perform
well for various reasons. A promising and simple strategy
for solving APEX detection problems is a modification of
the microarray design by replacement and rejection of the
ill-performing oligonucleotides. The analysis reported
above was based on an analysis of one DNA strand only.
Replacement of a primer by another oligonucleotide that
queries the corresponding position on the second DNA
strand is bound to improve overall detection efficiency,
since an entirely different primer sequence is used, which in
most cases is likely to perform well. This was demonstrated
for the analysis of the PR gene. For ten poorly detected
positions in codons 23, 30, 47, 60, 62, 63, 76 and 93,
oligonucleotides were replaced with primers for the second
DNA strand. Four samples with below-average concor-
dance values (less than 92%) were tested again in eight
repetitions on this second set of oligonucleotides. For all
samples, the new base calling accuracy at the individual
sites was in agreement with the sequence data. Although
new primers had been designed for only ten positions, even
the overall base calling accuracy increased significantly
compared to the unmodified primer set (Fig. 4). While the
replacement of individual primer oligonucleotides is time-
consuming using the a microarray system based on spotting
as reported here, the flexibility of micromirror-controlled in
situ synthesis could be utilised for this purpose [25]. In this
way, an optimisation process involving an iterative cycle of
probe design and experimental evaluation can be performed
rather quickly and cost-efficiently.
Data analysis
The information gained from the experiments was subjected to
a correspondence cluster analysis [26], which is an explorative
computational method for the investigation of associations
between variables, such as polymorphisms, and the individual
samples, in a multidimensional space. It simultaneously
displays data for two (or more) variables in a low-dimensional
projection, thus revealing associations between them. Figure 5
shows the results of clustering the data from the PR analysis.
The black dots represent individual polymorphisms, the red
squares the individual patient samples. Co-localisation of
samples in the blot is indicative of a strong association. It is
apparent that the samples separate into two subgroups.
Polymorphisms associated to one of these groups are plotted
in the same direction. There are only a few polymorphisms
which do not contribute to the discrimination of the samples,
located at the center of the plot (point 0/0) or along a line that
extends above or below this point. Data from more patients
with good clinical annotation is required in order to identify in
a statistically meaningful manner the variable that causes clear
division into (at least) two subgroups.
Conclusions
This study demonstrates the successful application of
APEX to genotypic drug resistance testing in HIV. Because
of the use of degenerated primers, the number of sensor
molecules could be kept relatively small. Nevertheless, the
assay is not restricted to the detection of primary mutations
in HIV. Instead, all resistance-related mutations presently
1668 Anal Bioanal Chem (2008) 391:1661–1669known to be associated with drug resistance could be
studied in a single experiment. With a slight decrease in the
number of degenerated bases introduced into primers that
bind to highly polymorphic sites, and by using primers for
both strands, a specificity and accuracy similar to an
analysis by standard Sanger sequencing can be achieved.
Considering that polymorphisms in the HIV PR and RT
genes are common, even among therapy-naïve patients, it
could happen in rare cases that an individual primer on the
microarray may not work for an individual patient—even
with an optimised set of oligonucleotide primers—because
of the presence of a mutation that is particular to this
patient. However, given the fact that there seem to be
subgroups of polymorphisms that are highly associated
with each other, such an event would most likely not
influence the overall outcome of the analysis. Even with the
current setup, both HIV subtype B and non-subtype B
samples can be analysed. Furthermore, the flexible array
design allows an uncomplicated inclusion of additional
oligonucleotides if necessary for this or other special
applications. Another attractive aspect of the assay is that the
entire procedure takes only a few hours, including data
analysis. Therefore, this microarray approach allows geno-
typic resistance testing in a high-throughput manner with an
accuracy that seems sufficient for routine clinical application.
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